BioSpace News Archive

INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its third quarter 2022, ended September 30, 2022, after the market close on Monday, November 14, 2022.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided a business update.

Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in November.

ACELYRIN, INC. announced two executive appointments that will strengthen leadership of key corporate functions as the company enters its next stage of growth: Mardi C. Dier joins as Chief Financial Officer and Chief Business Officer while Mina Kim joins as Chief Legal and Administrative Officer.

Atreca, Inc. today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments.

PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022.

Quanterix Corporation today announced that President and Chief Executive Officer Masoud Toloue and Chief Financial Officer Michael Doyle will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 17, 2022 at 4:30 p.m. EST in Boston, MA.

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today reported financial results for its fiscal year 2023 second quarter ended September 30, 2022 and provided a corporate update.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its third quarter 2022 financial results and highlighted recent corporate progress.

Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the quarter ended September 30, 2022, and provided a corporate update.